Boston Scientific Corporation
11/07/2024 | Press release | Distributed by Public on 11/07/2024 06:01
Regulation FD Disclosure Form 8 K
Item 7.01 Regulation FD Disclosure.
On November 7, 2024, Boston Scientific Corporation (the "Company") announced that it is resuming the AVANT GUARD clinical trial studying a new population of drug-naïve patients with persistent atrial fibrillation. The decision to resume enrollments in the trial was made following an assessment of observations within the trial and in conjunction with the study's data monitoring committee.
The information contained in Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.